BACKGROUND
Pulmonary hypertension (PH) is common in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), but the prognostic significance of periprocedural PH changes remains uncertain.
OBJECTIVES
This study sought to evaluate the association between periprocedural PH patterns and clinical outc...
J. Miyamoto, Yohei Ohno, S. Noda et al.· JACC: Cardiovascular Interve...· 1 citation
BACKGROUND
Bioprosthetic valve failure (BVF) is a key clinical endpoint for evaluating valve durability after transcatheter aortic valve implantation (TAVI). However, in populations with substantial competing mortality or heterogeneous follow-up durations, the estimated incidence of BVF may vary according to evaluation...
H. Hioki, M. Yamamoto, T. Shimura et al.· International Journal of Car...· 0 citations
BACKGROUND
Acute or advanced valve syndrome (AVS), originally proposed in aortic stenosis to describe rapid clinical deterioration, has not been evaluated in mitral regurgitation (MR).
OBJECTIVES
This study sought to investigate the prognostic impact of AVS in patients with primary MR undergoing mitral transcatheter...
D. Miyahara, Izumo Masaki, S. Kuwata et al.· JACC: Asia· 1 citation
Current guidelines offer limited guidance on the optimal timing of mitral transcatheter edge-to-edge repair (M-TEER) in degenerative mitral regurgitation (DMR). We evaluated whether the interval between diagnosis of DMR with heart failure (HF) and M-TEER was associated with clinical outcomes. We analyzed 1,061 patients...
T. Shimura, M. Yamamoto, I. Kawamura et al.· American Journal of Cardiolo...· 0 citations
In patients with ventricular functional MR and LVEF <20%, M-TEER was feasible and associated with meaningful symptomatic improvement without excess risk of death or HF hospitalization, although CV mortality remained higher, likely reflecting advanced myocardial disease.